Summary
The binding of amiodarone to human plasma protein and to bovine serum, albumin was studied by three different methods, ultracentrifugation, equilibrium dialysis and fluorescence spectroscopy. The fraction of amiodarone bound to plasma protein amounted to 96.3%. The changes in the binding properties of 1-anilino-naphthalene-8-sulfonate for bovine serum albumin using warfarin and amiodarone as independent inhibitors were analyzed in terms of binding site specificity. The findings indicated that amiodarone and warfarin have two different binding sites on bovine serum albumin, so a noncompetitive inhibition mechanism was indicated. On the basis of our data we cannot exclude other mechanisms of interaction besides direct displacement of one drug by another; nevertheless, metabolite interference between amiodarone and coagulation cofactors may better explain the enhancement of warfarin's pharmacological action in association with amiodarone.
Similar content being viewed by others
References
Rosenbaum, M. B., Chiale, P. A., Halpern, M. S., Nau, G. J., Przybylski, J., Levi, R. J., Lazzari, J. O., and Elizari, M. V., Am. J. Cardiol.38 (1976) 934.
Heger, J. J., Prystowsky, E. N., Jackman, W. M., Naccarelli, G. V., Warfel, K. A., Rinkenberger, R. L., and Zipes, D. P., New Engl. J. Med.305 (1981) 539.
Marcus, F. I., Fontaine, G. H., Frank, R., and Grosgogeat, Y., Am. Heart J.101 (1981) 480.
Latini, R., Tognoni, G., and Kates, R. E., Clin. Pharmacokinet.9 (1984) 136.
Kannan, R., Nademanee, K., Hendrickson, J. A., Rostami, H. J., and Singh, B. N., Clin. Pharmac. Ther.31 (1982) 438.
Storey, G. C. A., Adams, P. C., Nicholson, M. R., Campbell, R. W. F., and Holt, D. W., Br. J. clin. Pharmac.15 (1983) 148P.
Harris, L., McKenna, W. J., Rowland, E., Holt, D. W., Storey, G. C. A., and Krikler, D. M., Circulation67 (1983) 45.
Beck-Peccoz, P., Piscitelli, G., Volpi, A., Maggioni, A. P., Cattaneo, M. G., Giani, P., Landolina, M., Tognoni, G., and Faglia, G., in: Proc. Meeting Thyroid Disorders Associated with Iodine Deficiency and Excess, Freiburg, 24–26 April 1984.
Rees, A., Dalal, J. J., Reid, P. G., Henderson, A. H., and Lewis, M. J., Br. med. J.282 (1981) 1756.
Hamer, A., Peter, T., Mandel W. J., Scheinman, M. M., and Weiss, D., Circulation65 (1982) 1025.
Riva, E., Gerna, M., Latini, R., Giani, P., Volpi, A., and Maggioni, A., J. cardiovasc. Pharmac.4 (1982) 264.
Aarons, L., Clifton, P., Fleming, G., and Rowland, M., J. Pharm. Pharmac.32 (1980) 537.
Weder, H. G., Schildknecht, J., and Kesselring, P., Am. Lab.10 (1971) 15.
Weber, G., and You, L. B., J. biol. Chem.239 (1964) 1415.
Andreasen, F., Agerbaek, H., Bjerregaard, P., and Gøtzsche, H., Eur. J. clin. Pharmac.19 (1981) 293.
Bonati, M., Gaspari, F., D'Aranno, E., Benfenati, E., Neyroz, P., Galletti, F., and Tognoni, G., J. pharm. Sci.73 (1984) 829.
Bonati, M., Gohlke, J. R., and Rao, D. S., Biochemistry6 (1967) 3510.
Stryer, L., J. molec. Pharmac.13 (1965) 482.
Scatchard, G., Ann. N. Y. Acad. Sci.51 (1949) 660.
Klotz, I. M., Triwush, H., and Walker, F. M., J. Am. chem. Soc.70 (1948) 2935.
Jun, H. W., Luzzi, L. A., and Hsu, P. L., J. pharm. Sci.61 (1972) 1835.
Serlin, M. J., Sibeon, R. G., and Green, G. J., Br. med. J.283 (1981) 58.
Richard, C., Riou, B., Fournier, C., Rimailho, A., and Auzèpy, P., Circulation68, suppl. III (1983) A1122.
Author information
Authors and Affiliations
Additional information
This work was partially funded by the CNR (National Research Council, Rome, Italy), Program on Clinical Pharmacology and Rare Diseases. The authors would like to thanks Drs E. Marzi and E. riva for their help.
Rights and permissions
About this article
Cite this article
Neyroz, P., Bonati, M. In vitro amiodarone protein binding and its interaction with warfarin. Experientia 41, 361–363 (1985). https://doi.org/10.1007/BF02004505
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02004505